Facility Cited for Lack of Hazard Analysis and Misbranding
Following an inspection of a sprouting and noodle facility in early 2024, a 483 was issued. After FDA reviewed the firm’s response, a warning letter
Following an inspection of a sprouting and noodle facility in early 2024, a 483 was issued. After FDA reviewed the firm’s response, a warning letter
In a recent Insights article, TAG President and CEO Dr. David Acheson took a look back at 2024, noting how the “unusual” year had a